Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
59
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| PFIZER INC | Other | 1 | $0 | $0 | 2024-08-01 |
| Tregoning Kathleen | See Remarks | 14 | $0 | $260.4K | 2024-08-01 |
| Bodenrader Mark | See Remarks | 18 | $0 | $389.2K | 2024-08-01 |
| Renger John | Chief Scientific Officer | 91 | $0 | $16.13M | 2024-08-01 |
| Sanchez Ramiro | Chief Medical Officer | 21 | $0 | $1.57M | 2024-08-01 |
| ALTSCHULLER Susan | Chief Financial Officer | 9 | $0 | $571.9K | 2024-08-01 |
| Akamine Scott | Chief Legal Officer | 20 | $0 | $1.37M | 2024-08-01 |
| Burgess Paul D. | See Remarks | 9 | $501.7K | $0 | 2024-08-01 |
| Bain Capital Fund XII, LP | Director, 10% Owner | 2 | $0 | $0 | 2024-08-01 |
| Koppel Adam | Director, 10% Owner | 14 | $228.42M | $0 | 2024-08-01 |
| DiPietro Kenneth | Chief Human Resources Officer | 14 | $0 | $590.7K | 2024-08-01 |
| Mckernan Ruth | Director | 8 | $0 | $0 | 2024-08-01 |
| Gordon Christopher R | Director, 10% Owner | 14 | $228.42M | $0 | 2024-08-01 |
| Giordano Douglas E. | Director | 8 | $0 | $0 | 2024-08-01 |
| Renaud Ronald C JR | President & CEO | 12 | $2.01M | $0 | 2024-08-01 |
| Sulzberger Gabrielle | Director | 13 | $275.4K | $0 | 2024-08-01 |
| DEKKERS MARIJN E | Director | 12 | $0 | $6.89M | 2024-08-01 |
| COLES N ANTHONY | President and CEO | 84 | $0 | $30.40M | 2024-08-01 |
| RIEDEL NORBERT G | Director | 12 | $0 | $0 | 2024-08-01 |
| PATRICK DEVAL L | Director | 14 | $0 | $2.22M | 2024-08-01 |
| PERCEPTIVE ADVISORS LLC | Director | 4 | $4.83M | $0 | 2024-02-20 |
| EDELMAN JOSEPH | Director | 2 | $22.06M | $0 | 2023-10-16 |
| BAIN CAPITAL INVESTORS LLC | 10% Owner | 1 | $125.00M | $0 | 2023-10-16 |
| Ceesay Abraham | President | 20 | $0 | $3.26M | 2023-02-06 |
| PERCEPTIVE LIFE SCIENCES MASTER FUND LTD | Director | 4 | $84.88M | $0 | 2022-08-16 |
| PF Equity Holdings 1 B.V. | 10% Owner | 1 | $0 | $0 | 2022-03-31 |
| Yi Kathy | Chief Financial Officer | 2 | $0 | $0 | 2021-02-03 |
| Baron Deborah | Director | 1 | $0 | $0 | 2021-02-01 |
| MISHAN ORLY | Chief Business Officer | 2 | $0 | $0 | 2021-01-26 |
| BC Perception Holdings, LP | 10% Owner | 1 | $3.42M | $0 | 2020-11-09 |
| BCPE Perception GP, LLC | 10% Owner | 1 | $100.00M | $0 | 2020-10-27 |
| van Assche Wilfriede Margareta Maria | SVP & Gen. Counsel & Secretary | 37 | $0 | $65.1K | 2016-08-01 |
| Kuc Paul | Chief Financial Officer | 15 | $0 | $0 | 2016-08-01 |
| Hamilton Richard William | President and CEO | 11 | $0 | $0 | 2016-08-01 |
| Flavell Richard Bailey | Director | 38 | $0 | $212.8K | 2016-08-01 |
| Goldberg Robert Bruce | Director | 12 | $0 | $0 | 2016-08-01 |
| Brandys Pascal | Director | 23 | $0 | $0 | 2016-08-01 |
| MORLEY CHERYL P | Director | 6 | $0 | $0 | 2016-08-01 |
| GUIMARAES AFLALO SOUSA | Director | 2 | $0 | $0 | 2015-03-12 |
| Glat Daniel | Director | 3 | $0 | $0 | 2015-03-12 |
| Koonin Steven Elliot | Director | 4 | $0 | $0 | 2015-03-12 |
| KILEY THOMAS | Director | 11 | $0 | $0 | 2015-03-12 |
| Pennell Roger Ivan | VP of Trait Development | 6 | $0 | $0 | 2014-09-12 |
| De Logi Walter Kamiel Marie | Director | 6 | $0 | $0 | 2014-04-20 |
| Gwyn Joseph Jefferson | VP of Breeding and Genomics | 3 | $0 | $0 | 2014-03-25 |
| Artal Group S.A. | Director, 10% Owner | 1 | $0 | $0 | 2014-03-10 |
| Krieger David Benjamin | Director | 8 | $0 | $0 | 2014-03-07 |
| DEBBANE RAYMOND | Director | 3 | $0 | $0 | 2014-03-07 |
| Olivier de Vezin Edmund Martin | Director | 47 | $0 | $0 | 2013-08-21 |
| Stephenson Michael Francis | Vice President of Operations | 2 | $0 | $0 | 2013-05-06 |
| Suttles Douglas James | Director | 2 | $0 | $0 | 2013-03-21 |
| Ambergate Trust | 10% Owner | 7 | $1.31M | $0 | 2013-01-16 |
| Lynda De Logi Trust | 10% Owner | 21 | $2.00M | $0 | 2013-01-07 |
| Artal International S.C.A. | Director, 10% Owner | 1 | $0 | $0 | 2012-11-09 |
| Carlson Robert W Jr. | Other | 3 | $94.4K | $0 | 2012-06-01 |
| WARBURG PINCUS & CO. | Director, 10% Owner | 4 | $0 | $0 | 2012-02-27 |
| Stichting Administratiekantoor Westend | 10% Owner | 17 | $11.00M | $0 | 2012-02-27 |
| Warburg Pincus Partners LLC | Director, 10% Owner | 1 | $0 | $0 | 2012-02-21 |
| WESTEND SA | 10% Owner | 1 | $0 | $0 | 2012-02-21 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Burgess Paul D. | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 81,065 | — | $0 | 0 | SEC↗ |
| Burgess Paul D. | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 95,931 | — | $0 | 0 | SEC↗ |
| COLES N ANTHONY | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 46,322 | — | $0 | 0 | SEC↗ |
| COLES N ANTHONY | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 4,809,418 | — | $0 | 0 | SEC↗ |
| PATRICK DEVAL L | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 49,794 | — | $0 | 0 | SEC↗ |
| Bodenrader Mark | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 24,852 | — | $0 | 0 | SEC↗ |
| Bodenrader Mark | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 277,817 | — | $0 | 0 | SEC↗ |
| RIEDEL NORBERT G | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 95,242 | — | $0 | 0 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 124,168 | — | $0 | 0 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 81,065 | — | $0 | 0 | SEC↗ |
| DEKKERS MARIJN E | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 95,242 | — | $0 | 0 | SEC↗ |
| Tregoning Kathleen | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 614,428 | — | $0 | 0 | SEC↗ |
| Tregoning Kathleen | See Remarks | D To issuer deriv | 2024-08-01 | 2024-08-05 | 59,171 | — | $0 | 0 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | D To issuer deriv | 2024-08-01 | 2024-08-05 | 63,905 | — | $0 | 0 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | D To issuer deriv | 2024-08-01 | 2024-08-05 | 711,827 | — | $0 | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 15,061 | — | $0 | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 778,418 | — | $0 | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 87,573 | — | $0 | 0 | SEC↗ |
| Sulzberger Gabrielle | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 95,242 | — | $0 | 0 | SEC↗ |
| Akamine Scott | Chief Legal Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 367,126 | — | $0 | 0 | SEC↗ |
| Akamine Scott | Chief Legal Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 59,171 | — | $0 | 0 | SEC↗ |
| Mckernan Ruth | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 92,986 | — | $0 | 0 | SEC↗ |
| Renaud Ronald C JR | President & CEO | D To issuer deriv | 2024-08-01 | 2024-08-05 | 215,749 | — | $0 | 0 | SEC↗ |
| Renaud Ronald C JR | President & CEO | D To issuer deriv | 2024-08-01 | 2024-08-05 | 320,742 | — | $0 | 0 | SEC↗ |
| Renaud Ronald C JR | President & CEO | D To issuer deriv | 2024-08-01 | 2024-08-05 | 284,023 | — | $0 | 0 | SEC↗ |
| Giordano Douglas E. | Director | D To issuer deriv | 2024-08-01 | 2024-08-05 | 95,242 | — | $0 | 0 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 87,573 | — | $0 | 0 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | D To issuer deriv | 2024-08-01 | 2024-08-05 | 1,393,153 | — | $0 | 0 | SEC↗ |
| Koppel Adam | Director, 10% Owner | D To issuer deriv | 2024-08-01 | 2024-08-05 | 80,189 | — | $0 | 0 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | D To issuer deriv | 2024-08-01 | 2024-08-05 | 80,189 | — | $0 | 0 | SEC↗ |
| Burgess Paul D. | See Remarks | D To issuer | 2024-08-01 | 2024-08-05 | 45,727 | — | $0 | 0 | SEC↗ |
| COLES N ANTHONY | Director | D To issuer | 2024-08-01 | 2024-08-05 | 15,638 | — | $0 | 10,290 | SEC↗ |
| COLES N ANTHONY | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,290 | — | $0 | 0 | SEC↗ |
| PATRICK DEVAL L | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| PATRICK DEVAL L | Director | D To issuer | 2024-08-01 | 2024-08-05 | 3,282 | — | $0 | 10,461 | SEC↗ |
| Bodenrader Mark | See Remarks | D To issuer | 2024-08-01 | 2024-08-05 | 17,724 | — | $0 | 0 | SEC↗ |
| RIEDEL NORBERT G | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| RIEDEL NORBERT G | Director | D To issuer | 2024-08-01 | 2024-08-05 | 46,092 | — | $0 | 10,461 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | D To issuer | 2024-08-01 | 2024-08-05 | 16,913 | — | $0 | 0 | SEC↗ |
| DEKKERS MARIJN E | Director | D To issuer | 2024-08-01 | 2024-08-05 | 402,326 | — | $0 | 0 | SEC↗ |
| DEKKERS MARIJN E | Director | D To issuer | 2024-08-01 | 2024-08-05 | 31,822 | — | $0 | 10,461 | SEC↗ |
| DEKKERS MARIJN E | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Tregoning Kathleen | See Remarks | D To issuer | 2024-08-01 | 2024-08-05 | 10,666 | — | $0 | 0 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | D To issuer | 2024-08-01 | 2024-08-05 | 25,042 | — | $0 | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | D To issuer | 2024-08-01 | 2024-08-05 | 6,370 | — | $0 | 0 | SEC↗ |
| Sulzberger Gabrielle | Director | D To issuer | 2024-08-01 | 2024-08-05 | 48,415 | — | $0 | 10,461 | SEC↗ |
| Sulzberger Gabrielle | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Akamine Scott | Chief Legal Officer | D To issuer | 2024-08-01 | 2024-08-05 | 7,527 | — | $0 | 0 | SEC↗ |
| Mckernan Ruth | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Mckernan Ruth | Director | D To issuer | 2024-08-01 | 2024-08-05 | 3,282 | — | $0 | 10,461 | SEC↗ |
| Renaud Ronald C JR | President & CEO | D To issuer | 2024-08-01 | 2024-08-05 | 160,452 | — | $0 | 0 | SEC↗ |
| Renaud Ronald C JR | President & CEO | D To issuer | 2024-08-01 | 2024-08-05 | 83,857 | — | $0 | 0 | SEC↗ |
| Giordano Douglas E. | Director | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Giordano Douglas E. | Director | D To issuer | 2024-08-01 | 2024-08-05 | 3,282 | — | $0 | 10,461 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | D To issuer | 2024-08-01 | 2024-08-05 | 14,673 | — | $0 | 0 | SEC↗ |
| Koppel Adam | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 3,282 | — | $0 | 10,461 | SEC↗ |
| Koppel Adam | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Koppel Adam | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 65,679,781 | — | $0 | 0 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 10,461 | — | $0 | 0 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 3,282 | — | $0 | 10,461 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 65,679,781 | — | $0 | 0 | SEC↗ |
| Bain Capital Fund XII, LP | Director, 10% Owner | D To issuer | 2024-08-01 | 2024-08-05 | 65,679,781 | — | $0 | 0 | SEC↗ |
| PFIZER INC | Other | U Tender | 2024-08-01 | 2024-08-05 | 27,349,211 | $45.00 | $1.23B | 0 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-07-01 | 2024-07-03 | 25,000 | — | $0 | 2,177,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-07-01 | 2024-07-03 | 25,000 | $41.18 | $1.03M | 25,928 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-07-01 | 2024-07-03 | 25,000 | $3.50 | $87.5K | 50,928 | SEC↗ |
| Mckernan Ruth | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 13,743 | SEC↗ |
| Sulzberger Gabrielle | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 58,876 | SEC↗ |
| Giordano Douglas E. | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 13,743 | SEC↗ |
| RIEDEL NORBERT G | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 56,553 | SEC↗ |
| PATRICK DEVAL L | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 13,743 | SEC↗ |
| DEKKERS MARIJN E | Director | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 42,283 | SEC↗ |
| COLES N ANTHONY | Director | A Award | 2024-06-05 | 2024-06-07 | 10,290 | — | $0 | 25,928 | SEC↗ |
| Koppel Adam | Director, 10% Owner | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 13,743 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | A Award | 2024-06-05 | 2024-06-07 | 10,461 | — | $0 | 13,743 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-06-03 | 2024-06-05 | 50,000 | — | $0 | 2,202,417 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-06-03 | 2024-06-05 | 50,000 | $3.50 | $175.0K | 65,638 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-06-03 | 2024-06-05 | 50,000 | $40.61 | $2.03M | 15,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-05-10 | 2024-05-14 | 50,000 | — | $0 | 2,252,417 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-05-10 | 2024-05-14 | 50,000 | $3.50 | $175.0K | 65,638 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-05-10 | 2024-05-14 | 50,000 | $42.10 | $2.10M | 15,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-04-01 | 2024-04-03 | 50,000 | — | $0 | 2,302,417 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-04-01 | 2024-04-03 | 50,000 | $3.50 | $175.0K | 65,638 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-04-01 | 2024-04-03 | 50,000 | $42.33 | $2.12M | 15,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-03-04 | 2024-03-06 | 50,000 | — | $0 | 2,352,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-03-04 | 2024-03-06 | 50,000 | $41.01 | $2.05M | 15,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-03-04 | 2024-03-06 | 50,000 | $3.50 | $175.0K | 65,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-02-29 | 2024-03-04 | 50,000 | — | $0 | 2,402,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-02-29 | 2024-03-04 | 50,000 | $41.16 | $2.06M | 15,638 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-02-29 | 2024-03-04 | 50,000 | $3.50 | $175.0K | 65,638 | SEC↗ |
| PERCEPTIVE ADVISORS LLC | Director | G Gift | 2024-02-20 | 2024-02-21 | 170,317 | — | $0 | 0 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-02-07 | 2024-02-08 | 2,506 | $41.54 | $104.1K | 15,638 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2024-02-07 | 2024-02-08 | 2,161 | $41.54 | $89.8K | 6,370 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-02-06 | 2024-02-08 | 15,440 | — | $0 | 46,322 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2024-02-06 | 2024-02-08 | 5,020 | — | $0 | 15,061 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-02-06 | 2024-02-08 | 15,440 | — | $0 | 18,144 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2024-02-06 | 2024-02-08 | 5,020 | — | $0 | 8,531 | SEC↗ |
| Akamine Scott | Chief Legal Officer | A Award deriv | 2024-01-19 | 2024-01-23 | 59,171 | — | $0 | 59,171 | SEC↗ |
| Renaud Ronald C JR | President & CEO | A Award deriv | 2024-01-19 | 2024-01-23 | 284,023 | — | $0 | 284,023 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | A Award deriv | 2024-01-19 | 2024-01-23 | 87,573 | — | $0 | 87,573 | SEC↗ |
| Burgess Paul D. | See Remarks | A Award deriv | 2024-01-19 | 2024-01-23 | 81,065 | — | $0 | 81,065 | SEC↗ |
| Bodenrader Mark | See Remarks | A Award deriv | 2024-01-19 | 2024-01-23 | 24,852 | — | $0 | 24,852 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | A Award deriv | 2024-01-19 | 2024-01-23 | 63,905 | — | $0 | 63,905 | SEC↗ |
| Tregoning Kathleen | See Remarks | A Award deriv | 2024-01-19 | 2024-01-23 | 59,171 | — | $0 | 59,171 | SEC↗ |
| Renger John | Chief Scientific Officer | A Award deriv | 2024-01-19 | 2024-01-23 | 87,573 | — | $0 | 87,573 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | A Award deriv | 2024-01-19 | 2024-01-23 | 81,065 | — | $0 | 81,065 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2024-01-02 | 2024-01-04 | 50,000 | — | $0 | 2,452,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2024-01-02 | 2024-01-04 | 50,000 | $42.24 | $2.11M | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2024-01-02 | 2024-01-04 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise deriv | 2023-12-26 | 2023-12-28 | 10,000 | — | $0 | 538,435 | SEC↗ |
| Tregoning Kathleen | See Remarks | M Exercise deriv | 2023-12-26 | 2023-12-28 | 3,150 | — | $0 | 255,082 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | S Sale | 2023-12-26 | 2023-12-28 | 10,000 | $42.47 | $424.7K | 14,673 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise | 2023-12-26 | 2023-12-28 | 10,000 | $3.50 | $35.0K | 24,673 | SEC↗ |
| Tregoning Kathleen | See Remarks | M Exercise | 2023-12-26 | 2023-12-28 | 3,150 | $10.05 | $31.7K | 10,666 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | M Exercise deriv | 2023-12-22 | 2023-12-27 | 8,000 | — | $0 | 302,242 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | S Sale | 2023-12-22 | 2023-12-27 | 8,000 | $41.45 | $331.6K | 24,663 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | M Exercise | 2023-12-22 | 2023-12-27 | 8,000 | $3.50 | $28.0K | 32,663 | SEC↗ |
| Tregoning Kathleen | See Remarks | S Sale | 2023-12-20 | 2023-12-21 | 6,288 | $41.42 | $260.4K | 7,516 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | S Sale | 2023-12-20 | 2023-12-21 | 13,808 | $41.42 | $571.9K | 16,913 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | S Sale | 2023-12-20 | 2023-12-21 | 10,152 | $41.42 | $420.5K | 14,673 | SEC↗ |
| Akamine Scott | Chief Legal Officer | S Sale | 2023-12-20 | 2023-12-21 | 7,072 | $41.42 | $292.9K | 7,237 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | S Sale | 2023-12-20 | 2023-12-21 | 6,256 | $41.42 | $259.1K | 24,663 | SEC↗ |
| Bodenrader Mark | See Remarks | S Sale | 2023-12-20 | 2023-12-21 | 7,889 | $41.42 | $326.8K | 17,724 | SEC↗ |
| Tregoning Kathleen | See Remarks | M Exercise deriv | 2023-12-19 | 2023-12-21 | 13,804 | — | $0 | 0 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | M Exercise deriv | 2023-12-19 | 2023-12-21 | 30,721 | — | $0 | 0 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise deriv | 2023-12-19 | 2023-12-21 | 24,825 | — | $0 | 0 | SEC↗ |
| Renaud Ronald C JR | President & CEO | M Exercise deriv | 2023-12-19 | 2023-12-21 | 160,452 | — | $0 | 0 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise deriv | 2023-12-19 | 2023-12-21 | 13,796 | — | $0 | 0 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | M Exercise deriv | 2023-12-19 | 2023-12-21 | 13,913 | — | $0 | 0 | SEC↗ |
| Burgess Paul D. | See Remarks | M Exercise deriv | 2023-12-19 | 2023-12-21 | 23,847 | — | $0 | 0 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise deriv | 2023-12-19 | 2023-12-21 | 5,085 | — | $0 | 0 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise deriv | 2023-12-19 | 2023-12-21 | 14,199 | — | $0 | 0 | SEC↗ |
| Tregoning Kathleen | See Remarks | M Exercise | 2023-12-19 | 2023-12-21 | 13,804 | — | $0 | 13,804 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | M Exercise | 2023-12-19 | 2023-12-21 | 30,721 | — | $0 | 30,721 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise | 2023-12-19 | 2023-12-21 | 24,825 | — | $0 | 24,825 | SEC↗ |
| Renaud Ronald C JR | President & CEO | M Exercise | 2023-12-19 | 2023-12-21 | 160,452 | — | $0 | 160,452 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise | 2023-12-19 | 2023-12-21 | 13,796 | — | $0 | 14,309 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | M Exercise | 2023-12-19 | 2023-12-21 | 13,913 | — | $0 | 30,919 | SEC↗ |
| Burgess Paul D. | See Remarks | M Exercise | 2023-12-19 | 2023-12-21 | 23,847 | — | $0 | 45,727 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise | 2023-12-19 | 2023-12-21 | 14,199 | — | $0 | 20,528 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise | 2023-12-19 | 2023-12-21 | 5,085 | — | $0 | 25,613 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise deriv | 2023-12-15 | 2023-12-19 | 7,500 | — | $0 | 123,390 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | S Sale | 2023-12-15 | 2023-12-19 | 7,500 | $41.39 | $310.4K | 0 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise | 2023-12-15 | 2023-12-19 | 7,500 | $9.88 | $74.1K | 7,500 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise deriv | 2023-12-07 | 2023-12-07 | 10,000 | — | $0 | 254,262 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise deriv | 2023-12-07 | 2023-12-11 | 10,000 | — | $0 | 548,435 | SEC↗ |
| Akamine Scott | Chief Legal Officer | S Sale | 2023-12-07 | 2023-12-07 | 10,000 | $41.37 | $413.7K | 513 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise | 2023-12-07 | 2023-12-07 | 10,000 | $13.17 | $131.7K | 10,513 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | M Exercise | 2023-12-07 | 2023-12-11 | 10,000 | $3.50 | $35.0K | 10,000 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | S Sale | 2023-12-07 | 2023-12-11 | 10,000 | $41.37 | $413.7K | 0 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise deriv | 2023-12-05 | 2023-12-07 | 7,500 | — | $0 | 264,262 | SEC↗ |
| Akamine Scott | Chief Legal Officer | S Sale | 2023-12-05 | 2023-12-07 | 7,500 | $35.00 | $262.5K | 513 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise | 2023-12-05 | 2023-12-07 | 7,500 | $13.17 | $98.8K | 8,013 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-11-14 | 2023-11-16 | 22,824 | — | $0 | 2,502,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-11-14 | 2023-11-16 | 22,824 | $25.13 | $573.6K | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-11-14 | 2023-11-16 | 22,824 | $3.50 | $79.9K | 25,528 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-11-08 | 2023-11-09 | 100 | — | $0 | 2,525,241 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-11-08 | 2023-11-09 | 100 | $3.50 | $350 | 2,804 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-11-08 | 2023-11-09 | 100 | $25.16 | $2.5K | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-11-07 | 2023-11-09 | 27,076 | — | $0 | 2,525,341 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-11-07 | 2023-11-09 | 27,076 | $3.50 | $94.8K | 29,780 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-11-07 | 2023-11-09 | 27,076 | $25.02 | $677.4K | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-11-03 | 2023-11-06 | 61,401 | — | $0 | 2,552,417 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-11-03 | 2023-11-06 | 61,401 | $3.50 | $214.9K | 64,105 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-11-03 | 2023-11-06 | 61,401 | $25.43 | $1.56M | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-11-02 | 2023-11-06 | 38,599 | — | $0 | 2,613,818 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-11-02 | 2023-11-06 | 38,599 | $25.19 | $972.3K | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-11-02 | 2023-11-06 | 38,599 | $3.50 | $135.1K | 41,303 | SEC↗ |
| PATRICK DEVAL L | Director | M Exercise deriv | 2023-11-01 | 2023-11-03 | 30,130 | — | $0 | 12,555 | SEC↗ |
| PATRICK DEVAL L | Director | S Sale | 2023-11-01 | 2023-11-03 | 30,130 | $25.00 | $753.3K | 3,282 | SEC↗ |
| PATRICK DEVAL L | Director | M Exercise | 2023-11-01 | 2023-11-03 | 30,130 | $12.62 | $380.2K | 33,412 | SEC↗ |
| EDELMAN JOSEPH | Director | P Buy | 2023-10-16 | 2023-10-17 | 876,808 | $22.81 | $20.00M | 10,794,876 | SEC↗ |
| BAIN CAPITAL INVESTORS LLC | 10% Owner | P Buy | 2023-10-16 | 2023-10-18 | 5,480,052 | $22.81 | $125.00M | 65,679,781 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | P Buy | 2023-10-16 | 2023-10-18 | 5,480,052 | $22.81 | $125.00M | 65,679,781 | SEC↗ |
| Koppel Adam | Director, 10% Owner | P Buy | 2023-10-16 | 2023-10-18 | 5,480,052 | $22.81 | $125.00M | 65,679,781 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-09-07 | 2023-09-08 | 50,000 | — | $0 | 2,652,417 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-09-07 | 2023-09-08 | 50,000 | $24.07 | $1.20M | 2,704 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-09-07 | 2023-09-08 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| Burgess Paul D. | See Remarks | P Buy | 2023-08-04 | 2023-08-07 | 21,880 | $22.93 | $501.7K | 21,880 | SEC↗ |
| Renaud Ronald C JR | President & CEO | P Buy | 2023-08-03 | 2023-08-07 | 83,857 | $23.96 | $2.01M | 83,857 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise deriv | 2023-07-11 | 2023-07-13 | 50,000 | — | $0 | 2,702,417 | SEC↗ |
| COLES N ANTHONY | Director | M Exercise | 2023-07-11 | 2023-07-13 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | Director | S Sale | 2023-07-11 | 2023-07-13 | 50,000 | $30.03 | $1.50M | 2,704 | SEC↗ |
| Burgess Paul D. | See Remarks | A Award deriv | 2023-07-03 | 2023-07-06 | 23,847 | — | $0 | 23,847 | SEC↗ |
| Burgess Paul D. | See Remarks | A Award deriv | 2023-07-03 | 2023-07-06 | 95,931 | — | $0 | 95,931 | SEC↗ |
| DEKKERS MARIJN E | Director | S Sale | 2023-06-15 | 2023-06-20 | 200,000 | $34.43 | $6.89M | 402,326 | SEC↗ |
| Renaud Ronald C JR | President & CEO | A Award deriv | 2023-06-12 | 2023-06-14 | 160,452 | — | $0 | 160,452 | SEC↗ |
| Renaud Ronald C JR | President & CEO | A Award deriv | 2023-06-12 | 2023-06-14 | 160,371 | — | $0 | 160,371 | SEC↗ |
| Renaud Ronald C JR | President & CEO | A Award deriv | 2023-06-12 | 2023-06-14 | 215,749 | — | $0 | 215,749 | SEC↗ |
| DEKKERS MARIJN E | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| Mckernan Ruth | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| RIEDEL NORBERT G | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| PATRICK DEVAL L | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| Giordano Douglas E. | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| Sulzberger Gabrielle | Director | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| Koppel Adam | Director, 10% Owner | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | A Award deriv | 2023-06-07 | 2023-06-09 | 13,780 | — | $0 | 13,780 | SEC↗ |
| DEKKERS MARIJN E | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 31,822 | SEC↗ |
| Mckernan Ruth | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 3,282 | SEC↗ |
| RIEDEL NORBERT G | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 46,092 | SEC↗ |
| PATRICK DEVAL L | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 3,282 | SEC↗ |
| Giordano Douglas E. | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 3,282 | SEC↗ |
| Sulzberger Gabrielle | Director | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 47,853 | SEC↗ |
| Koppel Adam | Director, 10% Owner | J Other | 2023-06-07 | 2023-06-09 | 432,627 | — | $0 | 60,199,729 | SEC↗ |
| Koppel Adam | Director, 10% Owner | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 3,282 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | A Award | 2023-06-07 | 2023-06-09 | 3,282 | — | $0 | 3,282 | SEC↗ |
| Gordon Christopher R | Director, 10% Owner | J Other | 2023-06-07 | 2023-06-09 | 432,627 | — | $0 | 60,199,729 | SEC↗ |
| Bain Capital Fund XII, LP | 10% Owner | J Other | 2023-06-07 | 2023-06-12 | 432,627 | — | $0 | 60,199,729 | SEC↗ |
| Bodenrader Mark | See Remarks | S Sale | 2023-06-02 | 2023-06-05 | 1,895 | $32.95 | $62.4K | 5,522 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise deriv | 2023-06-01 | 2023-06-05 | 4,733 | — | $0 | 14,199 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-06-01 | 2023-06-05 | 50,000 | — | $0 | 2,752,417 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | A Award deriv | 2023-06-01 | 2023-06-05 | 124,168 | — | $0 | 124,168 | SEC↗ |
| ALTSCHULLER Susan | Chief Financial Officer | A Award deriv | 2023-06-01 | 2023-06-05 | 30,721 | — | $0 | 30,721 | SEC↗ |
| Bodenrader Mark | See Remarks | M Exercise | 2023-06-01 | 2023-06-05 | 4,733 | — | $0 | 7,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-06-01 | 2023-06-05 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-06-01 | 2023-06-05 | 50,000 | $32.60 | $1.63M | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-05-04 | 2023-05-08 | 50,000 | — | $0 | 2,802,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-05-04 | 2023-05-08 | 300 | $32.93 | $9.9K | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-05-04 | 2023-05-08 | 12,132 | $31.76 | $385.3K | 3,004 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-05-04 | 2023-05-08 | 37,568 | $31.36 | $1.18M | 15,136 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-05-04 | 2023-05-08 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-04-11 | 2023-04-13 | 50,000 | — | $0 | 2,852,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-04-11 | 2023-04-13 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-04-11 | 2023-04-13 | 50,000 | $25.06 | $1.25M | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-03-03 | 2023-03-06 | 3,000 | — | $0 | 2,902,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-03-03 | 2023-03-06 | 3,000 | $27.19 | $81.6K | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-03-03 | 2023-03-06 | 3,000 | $3.50 | $10.5K | 5,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-03-02 | 2023-03-06 | 47,000 | — | $0 | 2,905,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-03-02 | 2023-03-06 | 47,000 | $27.11 | $1.27M | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-03-02 | 2023-03-06 | 47,000 | $3.50 | $164.5K | 49,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-02-07 | 2023-02-08 | 50,000 | — | $0 | 2,952,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-02-07 | 2023-02-08 | 7,942 | $33.57 | $266.6K | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-02-07 | 2023-02-08 | 42,058 | $33.04 | $1.39M | 10,646 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-02-07 | 2023-02-08 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | A Award deriv | 2023-02-06 | 2023-02-08 | 13,913 | — | $0 | 13,913 | SEC↗ |
| DiPietro Kenneth | Chief Human Resources Office | A Award deriv | 2023-02-06 | 2023-02-08 | 54,749 | — | $0 | 54,749 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 24,825 | — | $0 | 24,825 | SEC↗ |
| Sanchez Ramiro | Chief Medical Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 97,691 | — | $0 | 97,691 | SEC↗ |
| Bodenrader Mark | See Remarks | A Award deriv | 2023-02-06 | 2023-02-08 | 20,012 | — | $0 | 20,012 | SEC↗ |
| Bodenrader Mark | See Remarks | A Award deriv | 2023-02-06 | 2023-02-08 | 5,085 | — | $0 | 5,085 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | A Award deriv | 2023-02-06 | 2023-02-08 | 243,042 | — | $0 | 243,042 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | A Award deriv | 2023-02-06 | 2023-02-08 | 61,762 | — | $0 | 61,762 | SEC↗ |
| Akamine Scott | Chief Legal Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 54,292 | — | $0 | 54,292 | SEC↗ |
| Akamine Scott | Chief Legal Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 13,796 | — | $0 | 13,796 | SEC↗ |
| Ceesay Abraham | President | A Award deriv | 2023-02-06 | 2023-02-08 | 29,083 | — | $0 | 29,083 | SEC↗ |
| Ceesay Abraham | President | A Award deriv | 2023-02-06 | 2023-02-08 | 114,445 | — | $0 | 114,445 | SEC↗ |
| Tregoning Kathleen | See Remarks | A Award deriv | 2023-02-06 | 2023-02-08 | 54,320 | — | $0 | 54,320 | SEC↗ |
| Tregoning Kathleen | See Remarks | A Award deriv | 2023-02-06 | 2023-02-08 | 13,804 | — | $0 | 13,804 | SEC↗ |
| Renger John | Chief Scientific Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 79,022 | — | $0 | 79,022 | SEC↗ |
| Renger John | Chief Scientific Officer | A Award deriv | 2023-02-06 | 2023-02-08 | 20,081 | — | $0 | 20,081 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2023-01-05 | 2023-01-06 | 50,000 | — | $0 | 3,002,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-01-05 | 2023-01-06 | 500 | $30.73 | $15.4K | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2023-01-05 | 2023-01-06 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2023-01-05 | 2023-01-06 | 49,500 | $29.93 | $1.48M | 3,204 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise deriv | 2022-12-09 | 2022-12-13 | 50,000 | — | $0 | 3,052,417 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2022-12-09 | 2022-12-13 | 5,145 | $27.09 | $139.4K | 2,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | M Exercise | 2022-12-09 | 2022-12-13 | 50,000 | $3.50 | $175.0K | 52,704 | SEC↗ |
| COLES N ANTHONY | CEO and Chairperson | S Sale | 2022-12-09 | 2022-12-13 | 44,855 | $26.62 | $1.19M | 7,849 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-11-01 | 2022-11-03 | 14,982 | — | $0 | 104,951 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-11-01 | 2022-11-03 | 10,018 | — | $0 | 60,110 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-11-01 | 2022-11-03 | 10,018 | $3.50 | $35.1K | 12,722 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2022-11-01 | 2022-11-03 | 25,000 | $30.00 | $750.0K | 2,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-11-01 | 2022-11-03 | 14,982 | $10.28 | $154.0K | 27,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-10-04 | 2022-10-06 | 10,018 | — | $0 | 70,128 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-10-04 | 2022-10-06 | 14,982 | — | $0 | 119,933 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2022-10-04 | 2022-10-06 | 25,000 | $30.00 | $750.0K | 2,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-10-04 | 2022-10-06 | 14,982 | $10.28 | $154.0K | 27,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-10-04 | 2022-10-06 | 10,018 | $3.50 | $35.1K | 12,722 | SEC↗ |
| PATRICK DEVAL L | Director | M Exercise deriv | 2022-09-12 | 2022-09-14 | 47,705 | — | $0 | 42,685 | SEC↗ |
| PATRICK DEVAL L | Director | S Sale | 2022-09-12 | 2022-09-14 | 47,705 | $30.78 | $1.47M | 0 | SEC↗ |
| PATRICK DEVAL L | Director | M Exercise | 2022-09-12 | 2022-09-14 | 47,705 | $12.62 | $602.0K | 47,705 | SEC↗ |
| Ceesay Abraham | President | M Exercise deriv | 2022-09-08 | 2022-09-12 | 19,210 | — | $0 | 365,009 | SEC↗ |
| Ceesay Abraham | President | M Exercise | 2022-09-08 | 2022-09-12 | 19,210 | $13.17 | $253.0K | 19,210 | SEC↗ |
| Ceesay Abraham | President | S Sale | 2022-09-08 | 2022-09-12 | 19,210 | $32.50 | $624.3K | 0 | SEC↗ |
| Ceesay Abraham | President | M Exercise deriv | 2022-08-22 | 2022-08-24 | 9,605 | — | $0 | 384,219 | SEC↗ |
| Ceesay Abraham | President | M Exercise | 2022-08-22 | 2022-08-24 | 9,605 | $13.17 | $126.5K | 9,605 | SEC↗ |
| Ceesay Abraham | President | S Sale | 2022-08-22 | 2022-08-24 | 9,605 | $32.50 | $312.2K | 0 | SEC↗ |
| PERCEPTIVE LIFE SCIENCES MASTE | Director | P Buy deriv | 2022-08-16 | 2022-08-18 | 0 | $100000000.00 | $0 | 0 | SEC↗ |
| PERCEPTIVE LIFE SCIENCES MASTE | Director | P Buy | 2022-08-16 | 2022-08-18 | 1,425,000 | $35.00 | $49.88M | 6,511,727 | SEC↗ |
| Ceesay Abraham | President | M Exercise deriv | 2022-08-15 | 2022-08-17 | 9,606 | — | $0 | 393,824 | SEC↗ |
| Ceesay Abraham | President | M Exercise | 2022-08-15 | 2022-08-17 | 9,606 | $13.17 | $126.5K | 9,606 | SEC↗ |
| Ceesay Abraham | President | S Sale | 2022-08-15 | 2022-08-17 | 9,606 | $34.12 | $327.8K | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-08-10 | 2022-08-12 | 25,376 | — | $0 | 134,915 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-08-10 | 2022-08-12 | 29,624 | — | $0 | 80,146 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2022-08-10 | 2022-08-12 | 18,859 | $41.10 | $775.1K | 2,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-08-10 | 2022-08-12 | 29,624 | $3.50 | $103.7K | 32,328 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-08-10 | 2022-08-12 | 25,376 | $10.28 | $260.9K | 57,704 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2022-08-10 | 2022-08-12 | 36,141 | $40.19 | $1.45M | 21,563 | SEC↗ |
| Ceesay Abraham | President | M Exercise deriv | 2022-08-08 | 2022-08-09 | 19,211 | — | $0 | 403,430 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise deriv | 2022-08-08 | 2022-08-09 | 10,000 | — | $0 | 271,762 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-08-08 | 2022-08-09 | 10,000 | — | $0 | 109,770 | SEC↗ |
| Ceesay Abraham | President | S Sale | 2022-08-08 | 2022-08-09 | 9,605 | $39.50 | $379.4K | 0 | SEC↗ |
| Ceesay Abraham | President | M Exercise | 2022-08-08 | 2022-08-09 | 19,211 | $13.17 | $253.0K | 19,211 | SEC↗ |
| Ceesay Abraham | President | S Sale | 2022-08-08 | 2022-08-09 | 9,606 | $37.75 | $362.6K | 9,605 | SEC↗ |
| Akamine Scott | Chief Legal Officer | M Exercise | 2022-08-08 | 2022-08-09 | 10,000 | $13.17 | $131.7K | 10,000 | SEC↗ |
| Akamine Scott | Chief Legal Officer | S Sale | 2022-08-08 | 2022-08-09 | 10,000 | $40.00 | $400.0K | 0 | SEC↗ |
| Renger John | Chief Scientific Officer | S Sale | 2022-08-08 | 2022-08-09 | 10,000 | $37.75 | $377.5K | 2,704 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise | 2022-08-08 | 2022-08-09 | 10,000 | $3.50 | $35.0K | 12,704 | SEC↗ |
| Ceesay Abraham | President | M Exercise deriv | 2022-08-05 | 2022-08-09 | 38,424 | — | $0 | 422,641 | SEC↗ |
| Renger John | Chief Scientific Officer | M Exercise deriv | 2022-08-05 | 2022-08-09 | 20,000 | — | $0 | 119,770 | SEC↗ |